A biomarker is, according to the US National Institutes of Health, 鈥渁 characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention.鈥�
Biomarkers make take the form of cellular characteristics, metabolites (e.g. sugars, lipids and hormones), molecular variations, or physical features (e.g., clinical symptoms) and are assessed accordingly, via measurement, annotation, documents, and images.
Increasingly, the discovery of novel biomarkers is closely associated with the advances in molecular biology techniques that can be accessed through analysis of DNA, RNA or proteins.
We can discriminate four main types of molecular biomarkers:
鈥� Genomic biomarkers: Based on the analysis of DNA (deoxyribonucleic acid) profiles, especially the analysis of SNPs (single nucleotide polymorphisms), i.e. identification of punctual variations in genomic DNA.
鈥� Transcriptomic biomarkers: Base on the analysis of RNA expression profiles.
鈥� Proteomic biomarkers: Base on the analysis of the protein profiles.
鈥� Metabolomic biomarkers: Base on the analysis of metabolites (metabolites are the intermediates and products of metabolism).
Commercializing biomarkers is the path that a biomarker could be used in therapeutic or diagnostic. In this report mainly covers consumables, services, software of this market.
The global market for Commercializing Biomarkers in Therapeutic and Diagnostic Applications was estimated to be worth US$ 21390 million in 2023 and is forecast to a readjusted size of US$ 29810 million by 2030 with a CAGR of 4.8% during the forecast period 2024-2030
The major players in global Commercializing Biomarkers in Therapeutic and Diagnostic Applications market include Roche, Dako (Agilent Technologies), Affymetrix, etc. The top 3 players occupy about 10% shares of the global market. North America and Europe are main markets, they occupy about 70% of the global market. Consumables is the main type, with a share about 60%. The main applications include Oncology, Cardiology, Neurology, etc.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Commercializing Biomarkers in Therapeutic and Diagnostic Applications, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Commercializing Biomarkers in Therapeutic and Diagnostic Applications by region & country, by Type, and by Application.
The Commercializing Biomarkers in Therapeutic and Diagnostic Applications market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Commercializing Biomarkers in Therapeutic and Diagnostic Applications.
麻豆原创 Segmentation
By Company
Roche
Dako (Agilent Technologies)
Merck
BD
Abbott
Genesys Biolabs (20/20GeneSystems)
Affymetrix
Agendia
ALMAC
Arrayit
Biocartic
BG Medicine
KEGG EXPRESSION Database
Thermo Fisher
BGI
Segment by Type:
Consumables
Services
Software
Segment by Application
Oncology
Cardiology
Neurology
Other
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Commercializing Biomarkers in Therapeutic and Diagnostic Applications manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Commercializing Biomarkers in Therapeutic and Diagnostic Applications in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Commercializing Biomarkers in Therapeutic and Diagnostic Applications in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 麻豆原创 Overview
1.1 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product Introduction
1.2 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications 麻豆原创 Size Forecast
1.3 Commercializing Biomarkers in Therapeutic and Diagnostic Applications 麻豆原创 Trends & Drivers
1.3.1 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Industry Trends
1.3.2 Commercializing Biomarkers in Therapeutic and Diagnostic Applications 麻豆原创 Drivers & Opportunity
1.3.3 Commercializing Biomarkers in Therapeutic and Diagnostic Applications 麻豆原创 Challenges
1.3.4 Commercializing Biomarkers in Therapeutic and Diagnostic Applications 麻豆原创 Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Players Revenue Ranking (2023)
2.2 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Company (2019-2024)
2.3 Key Companies Commercializing Biomarkers in Therapeutic and Diagnostic Applications Manufacturing Base Distribution and Headquarters
2.4 Key Companies Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product Offered
2.5 Key Companies Time to Begin Mass Production of Commercializing Biomarkers in Therapeutic and Diagnostic Applications
2.6 Commercializing Biomarkers in Therapeutic and Diagnostic Applications 麻豆原创 Competitive Analysis
2.6.1 Commercializing Biomarkers in Therapeutic and Diagnostic Applications 麻豆原创 Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Consumables
3.1.2 Services
3.1.3 Software
3.2 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Value by Type
3.2.1 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Value, by Type (2019-2030)
3.2.3 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Oncology
4.1.2 Cardiology
4.1.3 Neurology
4.1.4 Other
4.2 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Value by Application
4.2.1 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Value, by Application (2019-2030)
4.2.3 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Value by Region
5.1.1 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Value by Region (2019-2024)
5.1.3 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Value by Region (2025-2030)
5.1.4 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Value, 2019-2030
5.2.2 North America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Value, 2019-2030
5.3.2 Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Value, 2019-2030
5.4.2 Asia Pacific Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Value, 2019-2030
5.5.2 South America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Value, 2019-2030
5.6.2 Middle East & Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Value
6.3 United States
6.3.1 United States Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Value, 2019-2030
6.3.2 United States Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Value, 2019-2030
6.4.2 Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Value, 2019-2030
6.5.2 China Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Value by Type (%), 2023 VS 2030
6.5.3 China Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Value, 2019-2030
6.6.2 Japan Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Value, 2019-2030
6.7.2 South Korea Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Value, 2019-2030
6.8.2 Southeast Asia Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Value, 2019-2030
6.9.2 India Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Value by Type (%), 2023 VS 2030
6.9.3 India Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Roche
7.1.1 Roche Profile
7.1.2 Roche Main Business
7.1.3 Roche Commercializing Biomarkers in Therapeutic and Diagnostic Applications Products, Services and Solutions
7.1.4 Roche Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue (US$ Million) & (2019-2024)
7.1.5 Roche Recent Developments
7.2 Dako (Agilent Technologies)
7.2.1 Dako (Agilent Technologies) Profile
7.2.2 Dako (Agilent Technologies) Main Business
7.2.3 Dako (Agilent Technologies) Commercializing Biomarkers in Therapeutic and Diagnostic Applications Products, Services and Solutions
7.2.4 Dako (Agilent Technologies) Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue (US$ Million) & (2019-2024)
7.2.5 Dako (Agilent Technologies) Recent Developments
7.3 Merck
7.3.1 Merck Profile
7.3.2 Merck Main Business
7.3.3 Merck Commercializing Biomarkers in Therapeutic and Diagnostic Applications Products, Services and Solutions
7.3.4 Merck Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue (US$ Million) & (2019-2024)
7.3.5 BD Recent Developments
7.4 BD
7.4.1 BD Profile
7.4.2 BD Main Business
7.4.3 BD Commercializing Biomarkers in Therapeutic and Diagnostic Applications Products, Services and Solutions
7.4.4 BD Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue (US$ Million) & (2019-2024)
7.4.5 BD Recent Developments
7.5 Abbott
7.5.1 Abbott Profile
7.5.2 Abbott Main Business
7.5.3 Abbott Commercializing Biomarkers in Therapeutic and Diagnostic Applications Products, Services and Solutions
7.5.4 Abbott Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue (US$ Million) & (2019-2024)
7.5.5 Abbott Recent Developments
7.6 Genesys Biolabs (20/20GeneSystems)
7.6.1 Genesys Biolabs (20/20GeneSystems) Profile
7.6.2 Genesys Biolabs (20/20GeneSystems) Main Business
7.6.3 Genesys Biolabs (20/20GeneSystems) Commercializing Biomarkers in Therapeutic and Diagnostic Applications Products, Services and Solutions
7.6.4 Genesys Biolabs (20/20GeneSystems) Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue (US$ Million) & (2019-2024)
7.6.5 Genesys Biolabs (20/20GeneSystems) Recent Developments
7.7 Affymetrix
7.7.1 Affymetrix Profile
7.7.2 Affymetrix Main Business
7.7.3 Affymetrix Commercializing Biomarkers in Therapeutic and Diagnostic Applications Products, Services and Solutions
7.7.4 Affymetrix Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue (US$ Million) & (2019-2024)
7.7.5 Affymetrix Recent Developments
7.8 Agendia
7.8.1 Agendia Profile
7.8.2 Agendia Main Business
7.8.3 Agendia Commercializing Biomarkers in Therapeutic and Diagnostic Applications Products, Services and Solutions
7.8.4 Agendia Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue (US$ Million) & (2019-2024)
7.8.5 Agendia Recent Developments
7.9 ALMAC
7.9.1 ALMAC Profile
7.9.2 ALMAC Main Business
7.9.3 ALMAC Commercializing Biomarkers in Therapeutic and Diagnostic Applications Products, Services and Solutions
7.9.4 ALMAC Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue (US$ Million) & (2019-2024)
7.9.5 ALMAC Recent Developments
7.10 Arrayit
7.10.1 Arrayit Profile
7.10.2 Arrayit Main Business
7.10.3 Arrayit Commercializing Biomarkers in Therapeutic and Diagnostic Applications Products, Services and Solutions
7.10.4 Arrayit Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue (US$ Million) & (2019-2024)
7.10.5 Arrayit Recent Developments
7.11 Biocartic
7.11.1 Biocartic Profile
7.11.2 Biocartic Main Business
7.11.3 Biocartic Commercializing Biomarkers in Therapeutic and Diagnostic Applications Products, Services and Solutions
7.11.4 Biocartic Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue (US$ Million) & (2019-2024)
7.11.5 Biocartic Recent Developments
7.12 BG Medicine
7.12.1 BG Medicine Profile
7.12.2 BG Medicine Main Business
7.12.3 BG Medicine Commercializing Biomarkers in Therapeutic and Diagnostic Applications Products, Services and Solutions
7.12.4 BG Medicine Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue (US$ Million) & (2019-2024)
7.12.5 BG Medicine Recent Developments
7.13 KEGG EXPRESSION Database
7.13.1 KEGG EXPRESSION Database Profile
7.13.2 KEGG EXPRESSION Database Main Business
7.13.3 KEGG EXPRESSION Database Commercializing Biomarkers in Therapeutic and Diagnostic Applications Products, Services and Solutions
7.13.4 KEGG EXPRESSION Database Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue (US$ Million) & (2019-2024)
7.13.5 KEGG EXPRESSION Database Recent Developments
7.14 Thermo Fisher
7.14.1 Thermo Fisher Profile
7.14.2 Thermo Fisher Main Business
7.14.3 Thermo Fisher Commercializing Biomarkers in Therapeutic and Diagnostic Applications Products, Services and Solutions
7.14.4 Thermo Fisher Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue (US$ Million) & (2019-2024)
7.14.5 Thermo Fisher Recent Developments
7.15 BGI
7.15.1 BGI Profile
7.15.2 BGI Main Business
7.15.3 BGI Commercializing Biomarkers in Therapeutic and Diagnostic Applications Products, Services and Solutions
7.15.4 BGI Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue (US$ Million) & (2019-2024)
7.15.5 BGI Recent Developments
8 Industry Chain Analysis
8.1 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Industrial Chain
8.2 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Model
8.5.2 Sales Channel
8.5.3 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
Roche
Dako (Agilent Technologies)
Merck
BD
Abbott
Genesys Biolabs (20/20GeneSystems)
Affymetrix
Agendia
ALMAC
Arrayit
Biocartic
BG Medicine
KEGG EXPRESSION Database
Thermo Fisher
BGI
听
听
*If Applicable.